Pipeline news

• Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

  10 August 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of ZTALMY^® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of

• Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder

  31 July 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of ZTALMY^® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of

• Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus

  22 June 2023

  

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040.

• Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder

  26 May 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age. ZTALMY may be continued in patients 18 years of age and older.

• Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

  17 May 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

• Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

  11 May 2023

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.

• binx health and Mark Cuban Cost Plus Drug Company Team Up to Make Healthcare More Accessible and Affordable

  24 April 2023

  

  binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, and the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) are collaborating to increase access to affordable healthcare and necessary medications for patients across the nation. Together, the companies aim to reduce healthcare disparities and inequities. binx health offers online access to testing to diagnose common conditions such as diabetes, heart disease, and sexually transmitted infections (STIs). Through this collaboration, patients can access testing through binx health’s digital platform, binx everywhere, and receive affordable medication through Cost Plus Drugs online prescription program.

• Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel

  19 April 2023

  

  Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region. This panel is a key component of our comprehensive DefineMBC blood biopsy for metastatic breast cancer.

• Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

  18 April 2023

  

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors.

• binx health Further Expands Commercial Team in Support of Point-of-Care National Rollout

  17 April 2023

  

  binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announces the Company is expanding its commercial organization in response to a growing demand for its FDA-cleared, CLIA-waived, point-of-care (POC) testing platform for chlamydia (CT) and gonorrhea (NG). The binx io is the only molecular POC platform of its kind proven to detect CT and NG in male urine and female vaginal swab samples in about 30 minutes with performance equivalent to the central laboratory.